

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLORY 国瑞

Glory Health Industry Limited

國瑞健康產業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2329)

**QUARTERLY UPDATE
ON
ADDRESSING THE DISCLAIMER OF OPINION**

This announcement is made by Glory Health Industry Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company’s annual report for the year ended December 31, 2025 published on April 30, 2026 (the “**Annual Report**”). Unless otherwise defined herein, capitalized terms used in this announcement have the same meanings as those defined in the Annual Report.

The Board would like to provide the Shareholders and potential investors of the Company with the following updates regarding the Company’s measures in resolving the disclaimer of opinion:

- (a) The Group’s restructuring negotiations with financial institutions and other creditors are still in progress.
- (b) As disclosed in the Annual Report, the Group would sell part of its investment properties in order to improve the Group’s financial position, liquidity and cash flows, including the overall transfer of the Shenyang company, the overall transfer of the Foshan Shengpingli project, and the property sales project of Beijing North Fifth Building, are still in the stage of seeking buyers and conducting negotiations. Meanwhile, the Nanshan Project in Shenzhen, Xikeng Project in Shenzhen and Shantou Hospital Project are under planning to introduce strategic investors through multiple channels, optimise the debt structure and revitalise existing assets, so as to safeguard the overall liquidity security of the Company.

(c) The Group's work of applying to the government for the return of land for the Shenyang project and the Chongming Island project is still progressing continuously.

The Company will issue separate announcement(s) in a timely manner regarding the major progress of the above-mentioned matters under the Listing Rules and relevant laws and regulations as and when appropriate.

By Order of the Board
Glory Health Industry Limited
Zhang Zhangsun
Chairman

Beijing, the PRC, July 31, 2026

As at the date of this announcement, the Board comprises Mr. Zhang Zhangsun (Chairman), Ms. Ruan Wenjuan, Mr. Yuan Haibin, Mr. Zhao Yuhong and Ms. Zhang Xiaoqian as executive Directors; and Ms. Chen Jinrong, Mr. Deng Zhidong and Mr. Wang Shiyu as independent non-executive Directors.